June 9
Amaroq Therapeutics hits early milestones and makes key appointments to Scientific Advisory Board
Read more
Brandon BioCatalyst is the largest life science investment fund in Australia and New Zealand. We are a unique collaboration between major Australian superannuation funds, CSL, the Australian and New Zealand governments, Australian state governments and more than 50 leading medical research institutes and research hospitals.
Learn more about who we are
A proprietary blood collection tube rapidly providing high quality serum for analysis from all bloods including anti-coagulated
View ProjectTargeting long non-coding RNAs for next generation cancer therapies
View ProjectDeveloping the next generation of CAR-T cell therapies to treat solid cancers
View ProjectCombining non-opioid analgesics and biopolymers to deliver weeks of localised pain management
View ProjectUnlocking the potential of N-myristoyltransferase (NMT) to develop precision medicines for a range of diseases including cancer and viral infections
View ProjectGlyscend is developing novel non-absorbable polymers that are orally-delivered for the treatment of Type 2 Diabetes.
View ProjectUnderstanding life. Accelerating medical innovation. Promoting healthy communities.
ViewMater Research is a recognised leader in medical research. Our bench to bedside philosophy sees us working across Mater Health’s hospitals and health services, The University of Queensland, and the world-class Translational Research Institute (TRI).
ViewThe Brain Health Research Centre is one of the pre‐eminent neuroscience centres in NZ. It consists of more than 40 research groups (academic & clinical), plus their research staff and students across a number of schools and campuses in the Divisions of Health Sciences and Sciences at the University of Otago. The mission of the Brain Health Research Centre (BHRC) is to support excellent, international quality research at the University of Otago, aimed at understanding the mechanisms of brain health, disease and repair, including the development of new treatments for neurological disorders.
Brandon BioCatalyst is innovation in action: We provide a path for taking medical science from conception into the real world.
Our Venture capital model is unique. We don’t simply provide investment, we partner with entrepreneurs to create businesses, run companies and everything necessary to ensure our investments succeed.
Learn moreAmaroq Therapeutics hits early milestones and makes key appointments to Scientific Advisory Board
Read moreAustralian medical device company secures additional $12.5m to advance its breast cancer imaging system towards clinical trials
Read moreENA Respiratory Selected for BLUE KNIGHT™ to Accelerate Development of Pan-Antiviral Nasal Spray
Read moreGlyscend Therapeutics Announces Completion of Phase 1 Clinical Trial of its Oral, Gut-restricted, Polymer Therapeutic, GLY-200, as a Potential Type 2 Diabetes Treatment
Read more